摘要
巨细胞动脉炎(GCA)是中老年人的一种血管炎症症状，发病部位多为大中型动脉，尤以颞动脉为主，疾病的出现在一定程度上影响患者的身体健康。白细胞介素6在多种免疫反应和炎症反应中起重要作用。托珠单抗是一种人源化单克隆抗体，能特异性结合并阻断IL-6受体，抑制IL-6介导的信号转导，缓解炎症反应，减轻炎症损伤。本文分为四个部分，阐述了抗IL-6受体药物托珠单抗在巨细胞动脉炎免疫学作用的研究进展。首先，分析了托珠单抗的基本特性和作用机制，包括化学结构和生物活性、药代动力学特性、安全性等。其次对托珠单抗在巨细胞动脉炎治疗中的应用进行了探讨，包括疗效分析、剂量、疗程等，再次讨论了托珠单抗在巨细胞动脉炎治疗中的挑战与局限性，最后对该命题的前景进行了总结，希望本文能为相关人员的研究工作提供参考资料。
关键词： 抗IL-6受体药物；托珠单抗；巨细胞动脉炎；免疫调节作用；研究进展
Abstract
Giant Cell Arteritis (GCA) is an inflammatory symptom that affects blood vessels in middle-aged and elderly people. The disease involves large and medium-sized arteries in patients, especially the temporal arteries. The appearance of diseases affects the physical health of patients to a certain extent. Interleukin-6 plays an important role in a variety of immune responses and inflammatory responses. Tocilizumab is a kind of humanized monoclonal antibody that can bind and block the IL-6 receptor in a specific way, inhibit the IL-6 mediated signal transduction, alleviate inflammatory responses, and reduce inflammatory damage. This article is divided into four parts and describes the research progress of the immunomadological effects of anti-IL-6 receptor drug tocilizumab in giant cell arteritis. Firstly, the basic characteristics and mechanism of tocilizumab were analyzed, including chemical structure and biological activity, pharmacokinetic characteristics, and safety of tocilizumab. Secondly, the application of tocilizumab in the treatment of giant cell arteritis was discussed, including the efficacy analysis, dosage, and course of treatment. The challenges and limitations of tocilizumab in the treatment of giant cell arteritis were discussed again. Finally, the prospect of the proposition is summarized, hoping that this paper can provide reference materials for related personnel's research work.
Key words： Anti-IL-6 receptor drugs, Tocilizumab, Giant cell arteritis, Immunomodulatory effects, Research progress
参考文献 References
[1] Tan Yue, GE Ningning, Peng Jing, et al. Signal mining and evaluation of adverse drug events in children with tocilizumab and infliximab [J]. Chin J Clinical Pharmacology, 2024, 40 (05): 732-736.
[2] Albahdal S A, Alotaibi M A, Alanazi A M, et al. Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study [J]. Cost-effectiveness and Resource Allocation: C/E, 2024, 22 (1): 14.
[3] Zhang Xue, Li Dake. Rheumatic immune-related adverse reactions and treatment of immune checkpoint inhibitors [J]. Cancer Prevention and Treatment Research, 2020, 47 (11): 894-899.
[4] Zhang Weiqin, Zhao Huawei, Wang Zhenzhen, et al. Treatment of a child with refractory anti-NMDAR encephalitis with tocilizumab: case report and literature review [J/OL]. Chinese Modern Applied Pharmacy, 1-5 [2024-03-27].
[5] Liu Xiyu, Sun Mengyao, Ren Na, et al. The role of T cell-associated signaling pathways in the pathogenesis of Takayasu's arteritis [J]. Chin J Lab Diagnostics, 2023, 27 (04): 501-505.
[6] Han R. Diagnosis and treatment of a case of giant cell arteritis with paroxysmal visual impairment [J]. Chinese Journal of Practical Rural Doctor, 2022, 29 (01): 71-74.
[7] Zhu L S. The mechanism of Porphyromonas gingivalis affecting the immune response of macrophages and the screening of antibacterial Chinese medicine monomers [D]. Shanghai University of Traditional Chinese Medicine, 2021.
[8] Xi X Q. Giant cell arteritis and polymyalgia rheumatica [J]. Chinese Journal of Practical Rural Doctor, 2020, 27 (02): 9-11. (in Chinese)
[9] Tang Yanni, Yuan Yiming, Zhang Yingting. Giant cell arteritis with fever as the initial symptom: a case report [J]. Chin J Clinol (Electronic Edition), 2019, 13 (10): 798-800.
[10] Wang Yu, Zhang Yun, Wang Dongmei, et al. Clinical characteristics of giant cell arteritis with positive pathology and its correlation with pathological results [J]. Basic Medicine & Clinic, 2019, 39 (05): 731-734.
[11] Wu Xiao, Zheng Yuehong. Progress in diagnosis and treatment of giant cell arteritis causing intermittent claudication of the lower limbs [J]. Chin J Multiple Organ Diseases, 2018, 17 (08): 617-620.
[12] Chen Sufen, Zhang Meichen, Dong Zhao, et al. Clinical and prognostic analysis of giant cell arteritis patients presenting with pain. Chinese Journal of Pain Medicine, 2018, 24 (08): 610-614.
[13] Yin Yue, Zhang Yun, Zeng Xuejun. Giant cell arteritis and fever of unknown origin in the elderly [J]. Basic Medicine & Clinic, 2018, 38 (08): 1168-1172.
[14] GAO Kaiyan, Yuan Fenghong, Xu Wei, et al. PET-CT diagnosis of giant cell arteritis: report of 4 cases and review of literature [J]. Chongqing Med, 2017, 46 (33): 4673-4675+4679.
[15] Chen Xiaoming. The first drug Actemra(tocilizumab) approved by FDA for the treatment of giant cell arteritis [J]. Journal of Guangdong Pharmaceutical University, 2017, 33 (03): 289.
[16] Tong Chunmei. A case of posterior scleral inflammatory giant cell arteritis [J]. Chinese Journal of PLA Medicine, 2017, 29 (02): 2+117.
[17] Huang Huifang, Huo Lijuan, Guo Junzhi, et al. Giant cell arteritis diagnosed by positron emission computed tomography/CT: a case report with abdominal pain and fatigue [J]. Chin Materia Medica & Clinic, 2017, 17 (01): 151-152.
[18] Yuan Xiang, Li Xiaomei. Application of imaging techniques in the diagnosis of giant cell arteritis [J]. Chin J Clinical Immunology and Allergy, 2016, 10 (02): 170-174.
[19] Wang Limin, Yu Jing, Gao Mingli. Giant cell arteritis with fever as the first manifestation: a case report and literature analysis [J]. Shanxi Med J, 2016, 45 (09): 1083-1087.
[20] Wang Youying. Curative effect of giant cell arteritis and polymyalgia rheumatica [J]. Digest of World Latest Medical Information, 2015, 15 (A2): 90-91.
[21] T. Klink, J. Geiger, M. Both, et al. Giant cell arteritis: accuracy of MRI in the initial diagnosis of superficial cranial arteries: results from a multi-center trial [J]. International Journal of Medical Radiology, 2015, 38 (01): 78.